Parties d'ouvrages collectifs (6)
  1. 1. Simones, T., Shepherd, D. D., & Moser, M. (2010). Dendritic Cells. In C. A. McQueen & D. Lawrence (Eds.), Comprehensive Toxicology, Vol. 5. Immune System Toxicology (2 ed., pp. 155-170). Oxford: Elsevier Inc. doi:10.1016/B978-0-08-046884-6.00608-4
  2. 2. Moser, M. (2008). Dendritic cells. In W. Paul (Ed.), Fundamental immunology. Philadelphia, USA: Lippincott Williams and Wilkins.
  3. 3. De Heusch, M., Oldenhove, G., & Moser, M. (2006). Dendritic Cells (DCs) in Immunity and Maintenance of Tolerance. In H. Kropshofer & A. Vogt (Eds.), Antigen Presenting Cells: From Mechanisms to Drug Development (pp. 503-522). Wiley-VCH Verlag GmbH & Co. KGaA. doi:10.1002/3527607021.ch14
  4. 4. Moser, M. (2006). Antigen presentation, dendritic cells and autoimmunity. In N. Rose & I. Mackay (Eds.), The autoimmune diseases (pp. 37-46). Academic Press. doi:10.1016/B978-012595961-2/50007-X
  5. 5. Moser, M. (2003). Dendritic cells. In W. Paul (Ed.), Fundamental immunology (5 ed., pp. 455-480). Philadelphia, USA: Lippincott Williams and Wilkins.
  6. 6. Urbain, J., Vansanten, G., Demeur, C., Leo, O., Marvel, J., Moser, M., Tassignon, J., & Slaoui, M. (1986). From idiotypes to idiotypic network. In J. D. Capra & M. Reichlin (Eds.), Intern. Conference on Idiotypes (pp. 111-138). Acad. Press.
    7.   Articles dans des revues avec comité de lecture (139)
  7. 1. Gabrilo, J., Vande Velde, S., Henin, C., Denanglaire, S., Azouz, A., Boon, L., Van den Eynde, B. J., Moser, M., Goriely, S., & Leo, O. (2025). IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti-PD-1 Therapy in Tumor-Bearing Mice. Cancer immunology research, 13(12), 2004-2022. doi:10.1158/2326-6066.CIR-24-0835
  8. 2. Englebert, K., Taquin, A., Azouz, A., Acolty, V., Vande Velde, S., Vanhollebeke, M., Innes, H., Boon, L., Keler, T., Leo, O., Goriely, S., Moser, M., & Oldenhove, G. (2024). The CD27/CD70 pathway negatively regulates visceral adipose tissue-resident Th2 cells and controls metabolic homeostasis. Cell reports, 43(3), 113824. doi:10.1016/j.celrep.2024.113824
  9. 3. Bowakim-Anta, N., Acolty, V., Azouz, A., Yagita, H., Leo, O., Goriely, S., Oldenhove, G., & Moser, M. (2023). Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs. Frontiers in immunology, 14, 1023064. doi:10.3389/fimmu.2023.1023064
  10. 4. Mirzaei, M., Dodi, G., Gardikiotis, I., Pasca, S.-A., Mirdamadi, S., Subra, G., Echalier, C., Puel, C., Morent, R., Ghobeira, R., Soleymanzadeh, N., Moser, M., Goriely, S., & Shavandi, A. (2023). 3D high-precision melt electro written polycaprolactone modified with yeast derived peptides for wound healing. Biomaterials Advances, 149, 213361. doi:10.1016/j.bioadv.2023.213361
  11. 5. Bisilliat Donnet, C., Acolty, V., Azouz, A., Taquin, A., Henin, C., Cafarello, S. T., Denanglaire, S., Mazzone, M., Oldenhove, G., Leo, O., Goriely, S., & Moser, M. (2023). PHD2 Constrains Antitumor CD8+ T-cell Activity. Cancer immunology research, 11(3), 339-350. doi:10.1158/2326-6066.CIR-22-0099
  12. 6. Davenne, T., Percier, P., Larbanoix, L., Moser, M., Leo, O., Meylan, E., Goriely, S., Gérard, P., Wauthoz, N., Laurent, S., Amighi, K., & Rosiere, R. (2022). Inhaled dry powder cisplatin increases antitumour response to anti-PD1 in a murine lung cancer model. Journal of controlled release, 353, 317-326. doi:10.1016/j.jconrel.2022.11.055
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Suivant >>